Zuna and Behrens (7) reported that peritoneal cytology was rarely positive in patients who otherwise had pathologic stage I disease. This rules out a meaningful role for peritoneal washings in terms of therapeutic decision making. Far more significant is the danger of false-positive interpretation (because a large number of benign conditions might be reported as positive cytology due to suboptimal surgical technique, or pathologic misinterpretation, or both) with unnecessary aggressive therapy that might harm the patient. On the other hand, if the patient does well, the physician might erroneously credit the aggressive therapy with the success.
The authors, as well as the distinguished pathologist who wrote the accompanying editorial, insist that peritoneal washings remain a necessary adjunct in gynecologic cancers. To the clinical oncologist, however, the potential for harm from false-positive peritoneal cytology would appear to be far greater than the benefit from true-positive cytology in early stage cancers of the female genital tract.
BHADRASAIN VIKRAM Response
We thank Dr. Vikram for his interest in our paper (7) and welcome the opportunity to address his comments. Dr. Vikram focuses on the concern about false-positive interpretations in intraoperative peritoneal washing cytology in stage I gynecologic cancers. While false-positive interpretations are a serious matter, our experience suggests that Dr. Vikram's concerns may be overstated.
Dr. Vikram states that false-positive cytologies for pathologic stage I disease are a more substantial clinical problem than are true-positive cytologies. Our data do not support this statement. Delineation of cytologic pitfalls in these samples has been a major thrust of our work over the years (2, 3) [see also references (16-24) in reference (7)]. Indeed, one aspect of our current study was the validation of our diagnostic criteria in terms of survival data. Our data suggest that, with experience and attention to defined criteria, false-positive interpretations become extremely rare. While we indeed had relatively few pathologic stage I cancers with positive peritoneal cytology (ovary, 29.4%; endometrium, 0%; and cervix, 5.2%), these patients all died of cancer. Thus, we had no positive cytology case for which we erroneously attributed good survival to aggressive therapy (i.e., Dr. Vikram's "false-positive cytology").
Given the poor survival of our positive case patients, we are puzzled by Dr. Vikram's statement denying a "meaningful role for peritoneal washings in therapeutic decision making." In our experience, positive peritoneal washings in patients with any stage of disease were associated with dismal survival. In addition, we demonstrated survival differences in stage III ovarian cancer case patients on the basis of peritoneal cytology results.
With the use of our criteria, then, we do not see a greater danger from falsepositive cytology than from true-positive cases. Dr. Vikram is correct in that we should rethink the assumptions that were implicit in the rationale for peritoneal cytology when it was initiated. Today, a positive peritoneal washing in an otherwise early stage cancer patient should trigger critical reassessment, whereas in the past, it was often accepted without question. It is incumbent on those who render interpretations in these cases to be thoroughly familiar with the unique aspects of these samples. In troublesome cases, outside consultation should be sought from cytopathologists who have demonstrated expertise in this area. It is disconcerting to think that, despite the strong association of peritoneal cytology with survival in our study for all stages with sufficient numbers of patients, that the use of peritoneal washing cytology would be dismissed out of hand. We would agree with a suggestion to study a larger number of pathologic stage I case patients with positive peritoneal cytology and would welcome the opportunity to do so.
Finally, in our report, we proposed that the involvement of the peritoneal cavity was a biologically and therapeutically important event in the progression of malignant disease. We suggested that peritoneal cytology could be exploited as a marker in clinical trials for the stratification of patients and the development of therapies for intraperitoneal cancer. For this reason and those discussed above, we endorse the use of peritoneal cytology in primary surgeries for gynecologic cancers, as long as safeguards against false-positive interpretations are in place.
ROSEMARY E. ZUNA
